A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), Lovenox (Enoxaparin) Versus Heparin (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients.

Trial Profile

A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), Lovenox (Enoxaparin) Versus Heparin (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients.

Suspended
Phase of Trial: Phase III

Latest Information Update: 21 May 2016

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
    • 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.
    • 30 Mar 2016 Planned End Date changed from 1 Oct 2012 to 1 Mar 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top